These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36264321)

  • 1. [Batch testing as an essential pillar of the supply of safe and effective vaccines].
    Sediri-Schön H; Lange J; Grabski E; Wagner R; Hildt E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Dec; 65(12):1244-1250. PubMed ID: 36264321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Testing of vaccines. The challenge of testing complex combination vaccines].
    Merkle A; Lechner H; Oppling V; Meyer H
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1188-92. PubMed ID: 25204275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Official batch control of influenza vaccines: Is it still useful?
    Kretzschmar E; Muckenfuss H; Pfleiderer M
    Vaccine; 2018 Apr; 36(17):2364-2370. PubMed ID: 29580639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent control of COVID-19 vaccines by EU Official Control Authority Batch Release: challenges, strengths and successes.
    Milne C; Wagner R; Cano F; Bruysters M; Waeterloos G; Pullirsch D; Wierer M; Mallet L
    NPJ Vaccines; 2023 Feb; 8(1):22. PubMed ID: 36823287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Testing of medicinal products produced from pooled plasma].
    Unkelbach U; Hunfeld A; Breitner-Ruddock S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1181-4. PubMed ID: 25213735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Batch release of immunoglobulin and monoclonal antibody products].
    Gross S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1185-7. PubMed ID: 25200488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of the COVID-19 vaccination after broad implementation-an interim conclusion for Germany in July 2022].
    Siedler A; Schönfeld V; Peine C; Perumal N; Friedsam A; Stoliaroff-Pépin A; Harder T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Dec; 65(12):1272-1280. PubMed ID: 36355192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role, working methods and recommendations of the Standing Committee on Vaccinations (STIKO) in the context of the COVID-19 pandemic].
    Vygen-Bonnet S; Schlaberg J; Koch J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Dec; 65(12):1251-1261. PubMed ID: 36416888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerated national lot release on COVID-19 vaccines in Republic of Korea.
    Yang M; Lee N; Ju JH; Park IS; Hong JT; Oh HJ
    Biologicals; 2022 Jun; 77():24-27. PubMed ID: 35680495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The COVID-19 Vaccine: Trust, doubt, and hope for a future beyond the pandemic in Germany.
    Fiske A; Schönweitz F; Eichinger J; Zimmermann B; Hangel N; Sierawska A; McLennan S; Buyx A
    PLoS One; 2022; 17(4):e0266659. PubMed ID: 35390085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 vaccine trials: The use of active controls and non-inferiority studies.
    Fleming TR; Krause PR; Nason M; Longini IM; Henao-Restrepo AM
    Clin Trials; 2021 Jun; 18(3):335-342. PubMed ID: 33535811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Licensing and control authority batch release of influenza vaccine in Germany in accordance with EEC regulations.
    Weeke-Lüttmann M
    Eur J Epidemiol; 1994 Aug; 10(4):513-4. PubMed ID: 7843372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine Against Covid-19 Disease - Present Status of Development.
    Dutta AK
    Indian J Pediatr; 2020 Oct; 87(10):810-816. PubMed ID: 32880819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 vaccines.
    Ndwandwe D; Wiysonge CS
    Curr Opin Immunol; 2021 Aug; 71():111-116. PubMed ID: 34330017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Vaccines against COVID-19].
    Fathi A; Mellinghoff SC
    Internist (Berl); 2021 Nov; 62(11):1191-1201. PubMed ID: 34613428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allergen-specific immunotherapy and evidence: A European regulatory perspective.
    Bartel D; Bonertz A; Hartenstein D; Kaul S; Lauer I; Reeb C; Rösner-Friese K; Sliva K; Zimmer J; Vieths S; Mahler V
    Allergol Select; 2023; 7():198-210. PubMed ID: 38143937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of weekly COVID-19 vaccination and case data supports negative correlation between incidence and vaccination in German federal states and cities during 4th wave.
    Springer S; Kaatz M; Zieger M
    Vaccine; 2022 May; 40(22):2988-2992. PubMed ID: 35437192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of product batches (before and after registration). The German approach.
    Jungbäck C
    Dev Biol Stand; 1992; 79():171-4. PubMed ID: 1286753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of approved COVID-19 vaccines.
    Jamkhande A; Khairnar MR; Gavali N; Patil Y; Kapare SS; Bhosale KP
    Rocz Panstw Zakl Hig; 2021; 72(3):245-252. PubMed ID: 34553878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.